Community Trial in the Cherokee Nation

Sponsor
Emory University (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT04839978
Collaborator
National Institute on Drug Abuse (NIDA) (NIH)
1,000
1
2
34.1
29.4

Study Details

Study Description

Brief Summary

The target population is students attending high schools in small rural towns in the 14 counties that partially or fully fall within the Cherokee Nation reservation. Following recruitment of 20 school-based clusters, clusters are allocated to either the intervention condition or delayed-intervention control condition using constrained randomization. Constrained randomization helps to ensure balanced cluster sizes as well as similar levels of risk between the intervention and control at baseline. Study participants include all10th grade students enrolled in the participating study high schools and students will be followed into the first year after their expected graduation.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Connect Program
  • Behavioral: Communities Mobilizing for Change and Action (CMCA)
N/A

Detailed Description

The national public health opioid crisis has disproportionately burdened rural White populations, and disproportionately burdened American Indian populations. Therefore, the Cherokee Nation (CN) and Emory University public health scientists have designed an opioid prevention trial to be conducted in at-risk rural communities in the CN (in northeast Oklahoma) with primarily White and American Indian adolescents and young adults. The goal of this study is to implement and evaluate a theory-based, integrated multi-level community intervention designed to prevent the onset and escalation of opioid and other drug misuse. The researchers propose a cluster randomized trial building directly on the success of their most recent previous trial, which demonstrated that the intervention effectively reduced alcohol and other drug use among American Indian and other youth living within the CN. Two distinct intervention approaches-community organizing as implemented in the established Communities Mobilizing for Change and Action (CMCA) intervention protocol, and universal school-based brief intervention and referral as implemented in the established Connect intervention protocol -will be expanded and integrated to further enhance effects in preventing and reducing opioid misuse. The CMCA and Connect interventions were originally designed to target adolescent alcohol use, but nevertheless showed significant beneficial effects on use of other drugs, including prescription drug misuse. The proposed study will: (1) further improve the design of the interventions with increased focus on opioids, (2) test the expanded, integrated versions in a cluster randomized trial, and (3) design and test new systems for sustained implementation within existing structures of the Cherokee Nation. Building upon the extant prevention science evidence, this study will respond to a gap in evidence concerning opioid misuse prevention among at-risk adolescents transitioning to young adulthood among American Indian and other rural youth.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
1000 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Sixteen to 20 high schools and surrounding towns within the 14 counties that partially or fully fall within the Cherokee Nation reservation in northeast Oklahoma will be randomly assigned to receive the intervention right away or later. A total of 800 to 1200 students are expected to enroll from the randomized sites.Sixteen to 20 high schools and surrounding towns within the 14 counties that partially or fully fall within the Cherokee Nation reservation in northeast Oklahoma will be randomly assigned to receive the intervention right away or later. A total of 800 to 1200 students are expected to enroll from the randomized sites.
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Community Randomized Trial in the Cherokee Nation: Connect and CMCA for Preventing Drug Misuse Among Older Adolescents
Actual Study Start Date :
Sep 29, 2021
Anticipated Primary Completion Date :
Aug 1, 2024
Anticipated Study Completion Date :
Aug 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Preventive Intervention

Students in schools assigned to the preventive intervention study condition will take part in the Connect school-based prevention program and the community-level Communities Mobilizing for Change and Action (CMCA) intervention.

Behavioral: Connect Program
The Connect program includes school-based screening, brief intervention and referral, and will be treated as part of the participating schools' prevention programs. A computer-based screening and brief intervention will be supported by Cherokee Nation Behavioral Health (CNBH) supervised Connect coaches universally, to reduce potential stigma associated with speaking to a Connect coach and to reinforce drugfree norms among all students. Follow-up of moderate to high-risk youth will be conducted by a Connect Coach through Zoom, other electronic communication, or in-person visits, with referral to Cherokee Nation or community services if deemed necessary.

Behavioral: Communities Mobilizing for Change and Action (CMCA)
The community-level intervention Communities Mobilizing for Change and Action (CMCA) will involve educating and organizing of adult volunteers and consent will be assumed by their participation. We will provide trainings and tools, including Family Action Kits, to support local families, community organizations and citizens, including information on national and local opioid and other drug use, evidence-based policies, programs and practices, and how to motivate and create family and local action for drug prevention.

No Intervention: Delayed Intervention Control Group

Students in schools assigned to the control group will not receive the Connect and CMCA interventions. Schools in the control group will receive usual school and community prevention and be offered the trial's programs after this three-year study ends.

Outcome Measures

Primary Outcome Measures

  1. Change in Number of Days of Alcohol Use [Baseline up to 6 Months Post-Graduation]

    The number of days of alcohol use in the past 30 days will be compared between study arms.

  2. Change in Number of Days of Heavy Alcohol Use [Baseline up to 6 Months Post-Graduation]

    The number of days of heavy alcohol use in the past 30 days will be compared between study arms. Heavy alcohol use is defined as having at least four (among young women) or five (among young men) alcoholic drinks within a couple of hours.

  3. Change in Number of Days of Marijuana Use [Baseline up to 6 Months Post-Graduation]

    The number of days of marijuana use in the past 30 days will be compared between study arms.

  4. Change in Number of Days of Opioid Drug Misuse [Baseline up to 6 Months Post-Graduation]

    The number of days of prescription opioid misuse in the past 30 days will be compared between study arms.

Secondary Outcome Measures

  1. Change in Social Support [Baseline up to 6 Months Post-Graduation]

    Social support from parents/caregivers, friends, teachers, and community members is assessed with 24 items which are responded to on a 4-point scale where 0 = never and 3 = often. Total scores range from 0 to 72 and higher scores indicate greater support.

  2. Change in Perceived Availability of Drugs [Baseline up to 6 Months Post-Graduation]

    Ease or difficulty in accessing alcohol, marijuana, and prescription opioids is assessed with 12 items using a 4-point scale where 0 = very difficult to get and 3 = very easy to get. Total scores range from 0 to 36, with higher scores indicating greater ease of availability.

  3. Change in Social Normative Beliefs about Drug Use [Baseline up to 6 Months Post-Graduation]

    Participants will be asked 12 items to assess if they think various social groups disapprove of young people drinking alcohol, using marijuana, and prescription opioid misuse (parents, community adults, peers, self). Responses are given as 0 = don't disapprove, 1 = disapprove, and 2 = strongly disapprove. Total scores range from 0 to 24 with higher scores indicating stronger disapproval.

  4. Change in Self-Efficacy [Baseline up to 6 Months Post-Graduation]

    Self-efficacy is assessed with 4 items asking how easy or hard it would be for participants to ask for help or refuse alcohol or drugs. Responses given on a 4-point scale, where 0 = very easy and 3 = very hard. Total scores range from 0 to 12 and lower scores indicate increased self-efficacy.

  5. Change in Normative Estimates of Peer Drug Use [Baseline up to 6 Months Post-Graduation]

    Normative estimates of peer drug use (alcohol, marijuana, prescription opioid misuse) are assessed with 3 items asking about how many of their peers in school used drugs in the past year. Possible responses are 0 = none or almost none, 1 = less than half, 2 = about half, 3 = more than half, and 4 = almost all or all. Total scores range from 0 to 12 and higher scores indicate higher normative estimates of peer drug use.

Eligibility Criteria

Criteria

Ages Eligible for Study:
15 Years to 17 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Tenth grade students enrolled in the participating high schools
Exclusion Criteria:
  • unable to understand written or verbal English
Inclusion criteria for high schools:
  • Counties that partially or fully fall within the Cherokee Nation reservation

  • Town population of 3,000 or less

  • Class size between 30 to 100 students

Exclusion criteria for high schools:
  • Metropolitan and micropolitan cores (Rural-Urban Commuting Area codes of 1 and 4)

  • Existence of a community drug prevention coalition

Contacts and Locations

Locations

Site City State Country Postal Code
1 Cherokee Nation Reservation Tahlequah Oklahoma United States 74464

Sponsors and Collaborators

  • Emory University
  • National Institute on Drug Abuse (NIDA)

Investigators

  • Principal Investigator: Kelli Komro, PhD, Emory University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Kelli Komro, Professor, Emory University
ClinicalTrials.gov Identifier:
NCT04839978
Other Study ID Numbers:
  • STUDY00000404
  • UH3DA050234
  • UG3DA050234
First Posted:
Apr 9, 2021
Last Update Posted:
Jan 26, 2022
Last Verified:
Jan 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Kelli Komro, Professor, Emory University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 26, 2022